Levetiracetam Tablet, Extended Release
Product Images NDC 81665-100

6 FDA label images from Omnivium Pharmaceuticals Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 81665-100). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Omnivium Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Container Label (Container Label)

Container Label (Container Label)
Label for Levetiracetam Extended-Release Tablets, USP 750 mg by Omnivium Pharmaceuticals LLC. This pharmacy label highlights once daily dosing for oral extended-release tablets, contains 60 tablets, and includes storage and dispensing instructions. The label mentions the necessity of accompanying medication guide for patients.*
FDA Label Image

Figure 1 (Figure1)

Figure 1 (Figure1)
A bar chart comparing the percentage of patients with a specified outcome for three groups: Placebo (7.4%, N=95), Immediate-release Levetiracetam 1000 mg/day (37.1%, N=97), and Immediate-release Levetiracetam 3000 mg/day (39.6%, N=101). The chart highlights increased response with lefitiracetam doses versus placebo.*
FDA Label Image

Figure 2 (Figure2)

Figure 2 (Figure2)
Bar chart comparing the percentage of patients across three groups: Placebo, Immediate-release Levetiracetam 1000 mg/day, and Immediate-release Levetiracetam 2000 mg/day. The chart shows increasing patient response percentages with higher doses of Levetiracetam.*
FDA Label Image

Figure 3 (Figure3)

Figure 3 (Figure3)
A bar chart comparing the percentage of patients for two groups: Placebo (N=104) and Immediate-release Levetiracetam 3000 mg/day (N=180). The chart shows 14.4% for the placebo group and 39.4% for the immediate-release levetiracetam group, with the latter bar marked by an asterisk.*
FDA Label Image

Figure 4 (Figure4)

Figure 4 (Figure4)
A bar graph comparing the percentage of patients between placebo and immediate-release levetiracetam groups. The placebo group (N=97) shows 19.6% of patients, while the immediate-release levetiracetam group (N=101) shows 44.6% of patients. The graph highlights a difference in patient response rates between the two groups.*
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure of LEVETIRACETAM, showing its molecular arrangement with specific functional groups and stereochemistry as depicted in the diagram.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.